Results 231 to 240 of about 11,499 (250)

The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice

Diabetologia, 2018
Marta Olivares, Audrey M Neyrinck, Martin Beaumont   +2 more
exaly  

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Diabetologia, 2006
Niina Hanna Talvikki Matikainen, Marja-Riitta Taskinen   +1 more
exaly  

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2012
Margaretha Persson, Bo Ahrén
exaly  

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

Expert Opinion on Investigational Drugs, 2006
Bo Ahrén
exaly  

Covalent Inhibition Mechanism of Antidiabetic Drugs—Vildagliptin vs Saxagliptin

ACS Catalysis, 2019
Yong-Heng Wang, Ruibo Wu
exaly  

Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

Diabetes, Obesity and Metabolism, 2009
exaly  

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice, 2009
exaly  

Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study

Diabetes, Obesity and Metabolism, 2010
exaly  

Vildagliptin

Reactions Weekly, 2015
openaire   +1 more source

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

Diabetes, Obesity and Metabolism, 2008
exaly